drug · small molecule

ONDANSETRON HYDROCHLORIDE

Phase 3updated 2mo ago

by $RDY DR REDDYS LABORATORIES LTD🔗 ChEMBL

Phase 3

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 1 investigational indication.

targets

5-hydroxytryptamine receptor 3A

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

ONDANSETRON HYDROCHLORIDE

trade names

Demorem, Ondansetron hydrochloride, Ondansetron hydrochloride preservative free, Ondemet, Setofilm, Zofran

generic

ONDANSETRON HYDROCHLORIDE

MOA

12.1 Mechanism of Action Ondansetron is a selective 5-HT 3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT 3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetron’s antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine. In humans, urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion increases after cisplatin administration in parallel with the onset of emesis. The released serotonin may stimulate the vagal afferents through the 5-HT 3 receptors and initiate the vomiting reflex.

indication

1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . initial and repeat courses of moderately emetogenic cancer chemotherapy. radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen (1) postoperative nausea and/or vomiting (1)

phase

phase_3

ONDANSETRON HYDROCHLORIDE

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside